Torii Pharmaceutical Co Ltd
TSE:4551
Torii Pharmaceutical Co Ltd
Operating Income
Torii Pharmaceutical Co Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Torii Pharmaceutical Co Ltd
TSE:4551
|
Operating Income
¥6.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
37%
|
CAGR 10-Years
3%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Operating Income
¥479.5B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
33%
|
CAGR 10-Years
13%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Operating Income
¥265.3B
|
CAGR 3-Years
39%
|
CAGR 5-Years
13%
|
CAGR 10-Years
9%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Operating Income
¥416B
|
CAGR 3-Years
40%
|
CAGR 5-Years
19%
|
CAGR 10-Years
7%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Operating Income
¥542B
|
CAGR 3-Years
8%
|
CAGR 5-Years
20%
|
CAGR 10-Years
22%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Operating Income
-¥13.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Torii Pharmaceutical Co Ltd
Glance View
Torii Pharmaceutical Co., Ltd. engages in the manufacturing and marketing of pharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 560 full-time employees. The company went IPO on 2013-10-01. The Company’s main product categories include oral pruritus improving agents, proteolytic enzyme inhibitors, hyperkalemia improving agents, topical adrenocortical hormones, allergen immunotherapy for cedar pollinosis, allergen immunotherapy for mite allergy, active viable bacterial preparations, uterine contraction inhibitors in premature birth and others. The Company’s main products include Remitch, Riona tablets, Keixalate, Yulinome tablets, Antebate, Locoid, Zefnate, Sida Torengi pollen sublingual solution, Miticure mite sublingual tablet, Biosley, Magcent and others.
See Also
What is Torii Pharmaceutical Co Ltd's Operating Income?
Operating Income
6.8B
JPY
Based on the financial report for Dec 31, 2024, Torii Pharmaceutical Co Ltd's Operating Income amounts to 6.8B JPY.
What is Torii Pharmaceutical Co Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
3%
Over the last year, the Operating Income growth was 35%. The average annual Operating Income growth rates for Torii Pharmaceutical Co Ltd have been 13% over the past three years , 37% over the past five years , and 3% over the past ten years .
You don't have any saved screeners yet